Specifically, 10 potential therapeutic targets (AKT1, CASP3, IL6, JUN, MYC, MAPK3, SRC, STAT3, TNF, TP53) were directly linked to the KEGG pathway “hepatitis B” and were associated with 21 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZZS1, CL2, DSL4, ZJ10, ZJ6, DSL5, JTS1, TM12, XYS18; Table S2). The gene discussed is SRC; the disease is hepatitis B virus infection.